# Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma

> **NCT02652910** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Stage III Adult Diffuse Large Cell Lymphoma
- Stage III Follicular Lymphoma
- Stage III Mantle Cell Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma
- Stage IV Follicular Lymphoma
- Stage IV Mantle Cell Lymphoma

## Interventions

- **DRUG:** CD19.CAR-T cells

## Key facts

- **NCT ID:** NCT02652910
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652910, "Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02652910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*